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Kong SLE patients compared to standard care. METHODS: A lifetime 
microsimulation model was adapted with epidemiological and cost data from 
Hong Kong. The model compares the use of belimumab against standard care 
and incorporates the BLISS-52 and BLISS-76 trial data for the short term 
outcomes within one year, while long-term outcomes were based on a natural 
history model developed using the Johns Hopkins Lupus registry. The natural 
history model describes the relationship between disease activity and other 
covariates on the risk of dying and developing organ damage. Data available 
from the SLE population in Hong Kong was used as input in the modified model. 
The analysis was performed from a Hong Kong health-care perspective. In the 
base case, cost and effectiveness were discounted to the year of analysis at 5% 
p.a. RESULTS: The base case analysis showed that compared to standard care, 
treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) 
and QALY by 0.60 (1.68 undiscounted) years respectively. Total incremental costs 
were US$47,865 (US$80,460 undiscounted). The ICER of belimumab compared to 
standard care was US$59,546 per life year and US$79,407 per QALY gained. Hong 
Kong’s GDP per capita is US$35,961. Thus, this result is within the WHO 
recommended threshold for cost-effectiveness, at 3 times GDP of US$107,883. 
CONCLUSIONS: This study shows that belimumab would be cost-effective 
compared to standard care for the treatment of SLE in Hong Kong.  
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OBJECTIVES: Hemophilia B is a rare condition and evidence of specific health 
and economic outcomes for it are relatively scarce. The purpose of this study 
was to assess economic and health consequences of prophylaxis vs on-demand 
supply of factor IX (FIX) in young patients diagnosed with moderate/severe 
hemophilia B, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model followed 
moderate/severe hemophilia B patients starting at age 2 until they reached 18 
years. Patients in prophylaxis received 64.6 IU recombinant FIX/kg per infusion 
and 2.77 infusions every two weeks (same dose used in spontaneous bleeds), 
while patients in the on-demand arm received 69.4 IU plasma-derived FIX/kg to 
manage spontaneous bleeds. A literature review for outcomes in hemophilia B 
was performed (rates of bleeding with prophylaxis and on-demand therapy, 
average doses). Weight and probability of death per age correspond to the 
Mexican population. Avoided bleeds were the effectiveness measure used. The 
model does not consider other costs than FIX acquisition costs and emergency 
room, which were extracted from IMSS´s sources (except the cost of recombinant 
FIX, provided by the manufacturer). Costs are expressed in 2012 US$. Costs and 
consequences were discounted at 5%/annum. Univariate sensitivity analysis was 
performed. RESULTS: The prophylaxis group experienced 49% fewer bleeds than 
the on-demand group (39.11 vs. 83.32 per patient, respectively), however, this is 
reached with an incremental cost of $817,818.89 (cost of prophylaxis was 
$920,411.15, almost nine times the cost of on-demand). In spite of this, ICER for 
prophylaxis was $18,500.63/avoided bleed. The model is highly sensitive to 
probability of spontaneous bleeding, doses and cost of acquisition of FIX. 
CONCLUSIONS: At IMSS, prophylaxis with recombinant FIX for the management 
of patients with moderate/severe hemophilia B would be an intervention with 
strong health benefits worth the additional investment required.  
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OBJECTIVES: Hemophilia A is a disease with extreme disabling consequences. 
Prophylaxis helps to diminish them, but its cost should be assessed. The study 
was intended to estimate the economic and health consequences of prophylaxis 
vs on-demand supply of factor VIII (FVIII) in the management of patients with 
hemophilia A, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model simulated 
hemophilia in children from age 2 to 18 in two arms: prophylaxis with 
recombinant FVIII (25UI moroctocog alfa/kg every other day) and infusions of 
40UI/kg of plasma derived FVIII for spontaneous bleeds. The number of bleeds 
per approach, utilities and infusions required to control spontaneous bleeds 
were extracted from international literature. Both weight per age and probability 
of death were extracted from Mexican sources. Effectiveness measures were 
QALYs and bleeds avoided. The model assumed that safety and effectiveness 
profiles of both types of FVIII are equivalents, with no differences in costs of 
administration or adverse event management. Only the costs of acquisition of 
FVIII and emergency room were considered (both extracted from IMSS sources). 
Both costs and consequences were discounted at 5%/year. The costs are 
expressed in 2012 US$. Univariate sensitivity analysis was performed. RESULTS: 
There were 69% fewer bleeds in the prophylaxis group than in the on-demand 
group (50.7 vs 162.9, respectively), whereas the cost of prophylaxis represented 
5.6 times the cost of on-demand ($730,810 vs. $129,912, respectively), the ICER 
was $5,355.83/avoided bleed. Patients under prophylaxis gained 2.39 QALYs (9.88 
vs. 7.50), with an ICER of $251,876/QALY. The model is very sensitive to 
probability of spontaneous bleeding and dose in prophylaxis. CONCLUSIONS: 
From IMSS´s perspective, prophylaxis with moroctocog alfa for the management 
of patients with hemophilia A would bring highly valuable health benefits to 
patients, but more resources would need to be invested.  
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OBJECTIVES: Psoriasis is a chronic skin disease that strongly affects quality of 
life of its patients. In Ecuador, this disease affects 0.59% of the population and is 
estimated that 650 new patients are diagnosed every year with psoriasis 
according to the Ecuadorian National Foundation of Psoriasis. Biologic 
treatments had dramatically changed the therapeutics, outcomes and cost of 
management of these patients. The aim of this study is to assess the cost-
effectiveness of biologic alternatives available in Ecuador to treat moderate to 
severe psoriasis adult patients from a public payer’s perspective. METHODS: A 
decision-tree model was developed to simulate the clinical course of patients 
(18yrs+) treated with etanercept (50mg per week), adalimumab (80 mg on week 0, 
thereafter 40 mg every 2 weeks) and infliximab (5 mg/kg at weeks 0, 2, 6 and 
thereafter every 8 weeks) as first-line therapies, as well as treatment associated 
costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures 
were the percentage of patients reaching 75% improvement using the Psoriasis 
Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY´s). 
Costs considered included: biologic acquisition costs, concomitant medication, 
medical follow-up and side effects management. Clinical response of 
alternatives was extracted from published literature. Unit costs were collected 
from official Ecuadorian databases (Ministry of Health, National Social Security). 
RESULTS: After two years, the percentage of patients reaching PASI-75 were 
59.1%, 62.1% and 62.4% for adalimumab, etanercept and infliximab respectively 
(p=0.077, Friedman test). QALY´s associated to each alternative were: 1.50, 1.53 
and 1.53, respectively. Expected mean costs per patient were: US$ 66,240 for 
adalimumab; US$ 39,585 for etanercept and US$ 49,055.6 for Infliximab. These 
results were supported through probabilistic sensitivity analyses. 
CONCLUSIONS: In Ecuador, the less expensive therapy to treat moderate to 
severe adult psoriasis patients would be etanercept.  
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OBJECTIVES: Neuropathic pain is caused by various disorders affecting the 
central and peripheral nervous system. Its most common causes are secondary 
to herpes zoster infection and as a complication of diabetes mellitus. The aim of 
this analysis is to evaluate the cost-effectiveness of pregabalin versus duloxetine 
to estimate the pain reduction in diabetic neuropathy and postherpetic neuralgia 
from the social perspective in Colombia. METHODS: A Markov model was 
developed with 3 health-states: improvement (pain reduction >50% using visual 
analogue scale [VAS] against baseline), no improvement and treatment 
discontinuation (due to therapeutic failure). The time horizon is of 5 years (three-
month cycles) and discounts annually effectiveness and costs using a 3% rate. 
Comparators were pregabalin (150-300 mg/day) vs. duloxetine (60 mg/day). 
Population (>18 years) with neurophatic pain was estimated in 775,152 for 
Colombia. Effectiveness and utility data were taken from a literature and meta-
analysis of controlled clinical trials. Costs were taken from official tariff 
manuals, pricing laws and from the local health insurance company SURA. Costs 
are presented in 2012 USD. Effectiveness measure was Quality Adjusted Life 
Years (QALYs). RESULTS: Over a 5-year period, pregabalin obtained 231,105 
QALYs more than duloxetine (1,003,720 and 772,615 QALYs, respectively). Total 
expected savings with pregabalin was USD439.5M compared to duloxetine (total 
expected costs: USD664.8M and USD1,104.4M, respectively); costs for medical 
disabilities (sick leaves) were USD43.8 lower with pregabalin than duloxetine. 
Probabilistic sensitivity analyses showed the robustness of the model. 
CONCLUSIONS: Pregabalin is shown to be a cost-saving alternative compared 
with duloxetine for the treatment of neuropathic pain; pregabalin would have a 
higher rate of patients with reduction pain (51%) than duloxetine (41%), a larger 
number of QALYs and would have savings (USD567.1 per patient) due to lower 
costs of treatment and fewer payments for medical disabilities.  
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OBJECTIVES: Failed back surgery syndrome (FBSS) represents one main cause of 
chronic neuropathic or mixed pain. Clinical trials have shown that Spinal Cord 
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Stimulation (SCS) provides pain relief and improves patients’ health. We 
assessed in a naturalistic context the cost-utility of SCS in FBSS patients 
unresponsive to conventional medical management (CMM). METHODS: We 
conducted an observational, multicenter, longitudinal prospective study in 
which a sample of patients assigned to receive SCS in addition to CMM was 
observed for 24 months after the intervention. We collected before and after 
undergoing SCS the following data: direct and indirect costs, adopting the 
National Health Service (NHS) and the societal perspectives, pain status, using 
the Numerical Rating Scale (NRS, scoring from 0 (no pain) to 10 (maximum pain)), 
and HRQoL, using the SF-36 and EQ-5D. Costs and benefits pre-SCS versus post-
SCS were compared to estimate the incremental cost-effectiveness and the cost-
utility ratios. The following results focus on the cost/QALY ratio. RESULTS: 
Eighty patients (40% male, mean age 58 years) were recruited. Significant 
improvements in pain intensity and HRQoL were reached after 6 months from 
SCS and maintained or further improved until the end of the observational 
period. In particular, after 24 months from SCS the mean NRS significantly 
decreased (p<0.01) from 7.6 to 5.1, and the mean EQ-5D-utility significantly 
(p<0.01) increased from 0.07 to 0.40. The ICUR was equal to 27,519€/QALY, 
according to the NHS perspective. The cost-utility acceptability curve shows that 
if decision makers’ willingness-to-pay per QALY was 45,000€, then SCS 
implantation would be cost effective in 97% and 99% of cases, according to the 
societal and NHS perspectives, respectively. CONCLUSIONS: In a 2-year 
observational period, SCS+CMM treatment of FBSS patients increases medical 
direct costs but allows to improve significantly patients’ clinical health and 
HRQoL, resulting in a cost/QALY ratio largely lower than the commonly accepted 
willingness-to-pay threshold.  
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OBJECTIVES: Under the standard methods of health technology assessment 
(HTA) incorporating economic evaluation, orphan drugs do not usually prove to 
be cost-effective. Adding their high cost, it meant that funding and patient 
access may be limited in the Brazilian Public Health System (SUS). Acromegaly is 
one example, with annual incidence of 3-4 cases/million and prevalence of 40-90 
cases/million. There is a new drug, pegvisomant, which presents a relative 
efficacy at a high cost. With the objective to identify the best 
pharmacoeconomics evidence for pegvisomant in acromegaly and to review the 
knowledgment transfer to support a rapid economic review of rare diseases 
under the perspective of SUS. METHODS: In the case of the rare disease 
acromegaly a search was conducted on February 10th, 2013 using \’cost\’/exp OR 
cost AND effectiveness AND (\’pegvisomant\’/exp OR pegvisomant) AND 
(\’acromegaly\’/exp OR acromegaly) in Medline (PubMed), EMBASE, Virtual Health 
Library (BVS), Center for Reviews and Dissemination (CRD), The Cochrane 
Library. RESULTS: Only the study “Clinical effectiveness and cost-effectiveness of 
pegvisomant for the treatment of acromegaly: a systematic review and economic 
evaluation” was identified and selected. The study was conducted in the UK, 
where health costs are different from the Brazilian structure RESULTS: The 
study´s evidence indicates that pegvisomant is not cost-effective to treat 
pacients with resistant agromegaly. In Brazil the cost of each dose in the public 
health system is about 25% more expensive than the UK, and so is the cost of 
labor. CONCLUSIONS: The need of economic assessment transferability as a tool 
to support the management of political decisions, especially to high cost 
technologies and rare diseases, are not set as priority in the research fostering 
agenda of the SUS  
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OBJECTIVES: Type I Gaucher disease (GD) is an autosomal recessive disorder 
caused by a deficiency in β-glucocerebrosidase enzyme, causing 
hepatosplenomegaly, anaemia, trombocitopenia, bone injuries and other 
complications. Intravenous enzyme replacement therapy (ERT) is the current 
standard of care, which has demonstrated in several studies its efficacy in  
the prevention and amelioration of progressive and systemic manifestations. 
Velaglucerase alpha is a glycoprotein with the same amino acid sequence as the 
human enzyme β-glucocerebrosidase. The aim of this study is to assess the cost-
effectiveness of velaglucerase alpha versus imiglucerase for the treatment  
of type 1 GD from the perspective of the Spanish National Healthcare System 
(NHS). METHODS: A cost-utility analysis was performed using a semi-Markov 
model that embedded one decision tree for the initial treatment during two 
years and a Markov health state structure after the response to the second year 
receiving ERT, from the NHS perspective. The Markov framework was structured 
around six health states: asymptomatic, mild, moderate, severe, splenectomy 
and death and used annual cycles with a time horizon of 39 years. Model 
structure was validated by a panel of GD experts. Efficacy data were obtained 
from the HGT-GCB-039 study. Resources consumption was based on expert 
opinion. Outcomes were quality-adjusted life years (QALY) and costs (€ in 2011). 
Threshold sensitivity analysis was conducted to determine cost-neutrality 
between strategies. RESULTS: Both strategies provided a mean gained of 25.55 
QALYs. The average cost per patient for velaglucerase alpha was €7,265,332 
compared to €7,327,966 for imiglucerase. The difference in costs was mainly due 
to the difference in administration costs. The threshold sensitivity analysis 
showed that velaglucerase alpha will reach cost-neutrality even with a higher 
unit price. CONCLUSIONS: Velaglucerase alpha is a cost-saving option for the 
treatment of type 1 GD in the Spanish setting, providing annual savings 
compared with imiglucerase. (This study was supported by Shire 
Pharmaceuticals Iberica)  
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OBJECTIVES: The purpose of this study was to conduct an economic analysis  
of clinical effectiveness of antiviral drugs in monotherapy (entecavir, 
lamivudine, telbivudine, tenofovir, peginterferon alfa-2a) compared with  
no specific treatment for patients with chronic hepatitis B in Russia. METHODS: 
Clinical-economic study was carried out with the Markov model.The duration of 
one cycle-1 year,the duration of antiviral treatment-5 years.As a measure  
of utility QALY were used. Due to the absence of Russian studies, a multinational 
study from 2008 was used. RESULTS: Total cost of one year of treatment  
of chronic hepatitis B were: lamivudine-35732.97 rubles, for entecavir-96104.00 
rubles for tenofovir-103279.55,for telbivudine-116933.75 for peginterferon-alfa-
2a-502238.40 rubles. The lowest cost-utility ratio (CUR) was for lamivudine-
91159.54 rubles/QALY. The highest CUR is for pegylated interferon alfa-2a and 
then tenofovir/entecavir-183263.00 rubles/QALY and 176936.58 rubles/QALY, 
respectively. More cost-effective treatment is to start with the third- 
line drugs-entecavir/tenofovir. The study showed that the use of 
entecavir,lamivudine,tenofovir is clinically and economically more effective than 
using no specific antiviral therapy.The CURs for these tactics is lower than that 
for the natural course of the disease.More effective from a clinical and economic 
point of view, for the treatment of chronic hepatitis B is to use as single one  
of these:entecavir/tenofovir/lamivudine. CONCLUSIONS: The quality of life  
of patients with chronic hepatitis B without the specific treatment will be lower 
than that with the antiviral drugs,since without the treatment increases the  
rate of formation of severe fibrosis in the liver, there is a quicker outcome to 
cirrhosis and other complications.Lowest CUR is for lamivudine due to the low 
cost of it,but the high rate of resistance to lamivudine and the need to add  
additional third-generation drug may increase the cost.The highest  
CUR is with administering pegylated interferon-alfa-2a and then  
applying tenofovir/entecavir. It seems economically feasible to begin therapy 
immediately with the administration of the third generation drug - entecavir or 
tenofovir.  
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OBJECTIVES: Few studies have reported the impact of laparoscopic adjustable 
gastric banding (LAGB) on work productivity in obese patients. The objective of 
this HERO study analysis is to examine the effect of weight loss (WL) on work 
productivity (absenteeism, presenteeism, and productivity loss) and non-work 
activity impairment 1 year (yr) after laparoscopic placement of LAP-BAND AP® 
System. METHODS: HERO is a 5-yr registry of 1,106 obese patients from 29 
centers in the United States (US), Canada, Europe, and Australia who underwent 
LAGB. Our descriptive analysis included about 70% of subjects who provided 
complete baseline (BL) and 1 yr health related quality of life data based on Work 
Productivity and Activity Impairment questionnaire, a well validated instrument 
generating scores in absenteeism, presenteeism, work productivity loss and non-
work activity impairment. RESULTS: The mean age was 43.1 yrs and females 
constituted 79.3%. At BL, 59% worked full time and 10% worked part time. Mean 
(SD) baseline weight was 126.2 (24.14) kg. At 1 year, the average %WL was 16.9% 
(SD, 9.02). Baseline presenteeism was 4.5%, absenteeism 33.4%, work productivity 
3.8%, and non-work activity impairment was 51.2%. At 1 year, there was 
reduction in presenteeism to 2.8% (p<0.05), in absenteeism to 20% (p<0.05), in 
work productivity to 2.3% (p<0.05), and non-work activity impairment to 28% 
(p<0.05). There was a decreasing trend in presenteeism (23.4%, 20.4%, 18.2%, 
14.1%, p=0.01) and less non-work activity impairment (32.9%, 29.7%, 22.7%, 17.5%, 
p<0.001) as %WL increased from 0-10%, to >10-20%, to >20-30%, and to >30%. 
This decrease was not observed with absenteeism (1.9%, 3.8%, 2.5%, 1.7%, p=0.28) 
nor productivity loss (2.1%, 2.2%, 2.7%, 1.8%, p=0.74) as %WL increased. 
CONCLUSIONS: LAGB was associated with significant WL and improvement in 
work productivity and reduction in non-work activity impairment by 1 yr. 
Further analysis will examine the sustainability of WL effect on impact on work 
productivity.  
 
PSY51  
COST TO SOCIETY DUE TO UNDEREMPLOYMENT IN PERSONS WITH 
HEMOPHILIA A AND B – HEMOPHILIA UTILIZATION GROUP STUDY V (HUGS V)  
